Our complimentary white papers draw on our primary research findings to provide you information on critical life sciences topics. Please fill out the short form accompanying each white paper in the list below. You will then be directed to links to the downloadable PDFs.
Click the download button below to get access to a complimentary white paper.
If you have questions, call (919) 403-6583.
Latest White Papers
Pharmaceutical Key Account Management: Harnessing Sales Expertise to Develop Unified Stakeholder Relationships 2016
Instead of relying on a host of field forces, some companies are implementing key account management (KAM) teams to work closely with their largest commercial accounts. These emerging field forces are charged with building long-lasting, mutually beneficial relationships with large physician networks, pharmacies and wholesalers, private and government payers, and hospital systems.
Life Science Commercial Boards: Establishing A Cross-Functional Strategy To Support Emerging Products 2016
Facing an increasingly complex commercial landscape, life science companies must rely on regular input from in-house experts to guide their products from early development to launch. Brand commercialization committees combine cross-functional voices to create cohesive strategies for developing drugs and devices. These committees allow marketing stakeholders to best understand the initiatives, timelines and challenges impacting individual brands’ development and launches.
Exciting Trends in Medical Affairs 2016
Medical affairs is evolving into a strategic function invaluable to healthcare decision makers and the internal organizations of life science companies. While there are many parts to this evolution, this paper highlights three points. First, medical affairs trend show the MSL role is expanding beyond relationship-building. Today, MSLs are getting involved in clinical trials, aid in payer discussions and bring insights back to the internal organization. Second, healthcare decision makers increasingly emphasize real-world evidence, and Phase 4 teams are innovating trial designs that go beyond standard randomized controlled trials to get a closer look at product effectiveness, utilization and costs in a clinical setting with a diverse patient population. Finally, the demand to prove value encourages medical affairs to bring strategic insights to the internal organization. These insights can inform company strategies and demonstrate how medical affairs’ value relates to both external and internal stakeholders.
PURCHASE OUR FULL STUDY:
Ensuring Compliant TMF Practices: Common Regulatory Inspection Pitfalls and How to Avoid Them 2016
This white paper provides a series of recommendations to help pharmaceutical and medical device teams fine-tune their TMF management operations. Internal teams must ensure that sponsor-managed files are comprehensive and reflect the standards of Good Clinical Practice (GCP). Findings from European and British regulatory agencies’ inspections highlight the aspects of TMF management that companies are likely to find most challenging.